JonathanSteinfeldMD

PubMed

• 1 citations
  Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
  Jayne, D., Terrier, B., Hellmich, B., Baylis, L., Bentley, J., Yancey, S., Kwon, N., Khoury, P., Steinfeld, J., Wechsler, M., Akuthota, P.> ;ERJ Open Research. 2024 Jan 1
• 1 citations
  Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
  Benjamin Terrier, David R W Jayne, Bernhard Hellmich, Jane H Bentley, Jonathan Steinfeld, Steven W Yancey, Namhee Kwon, Praveen Akuthota, Paneez Khoury, Lee Baylis, Mi...> ;ACR Open Rheumatology. 2023 Jul 1
• 9 citations
  Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
  Marc E Rothenberg, Florence Roufosse, Stanislas Faguer, Gerald J Gleich, Jonathan Steinfeld, Steven W Yancey, Eleni Mavropoulou, Namhee Kwon> ;The Journal of Allergy and Clinical Immunology. in Practice. 2022 Sep 1
• 18 citations
  Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
  Gema Requena, Judith van den Bosch, Praveen Akuthota, Anna Kovalszki, Jonathan Steinfeld, Namhee Kwon, Melissa K Van Dyke> ;The Journal of Allergy and Clinical Immunology. in Practice. 2022 Aug 1
• 3 citations
  Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
  Andreas Reiter, Guillaume Lefevre, Maria C Cid, Namhee Kwon, Eleni Mavropolou, Steven W Yancey, Jonathan Steinfeld> ;Frontiers in Immunology. 2022 Jan 1
• 2 citations
  Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
  Fabrizio Pane, Guillaume Lefevre, Namhee Kwon, Jane H Bentley, Steven W Yancey, Jonathan Steinfeld> ;Frontiers in Immunology. 2022 Jan 1
• 21 citations
  From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases
  Ian D. Pavord, Elisabeth H. Bel, Arnaud Bourdin, Robert Chan, Joseph K. Han, Oliver N. Keene, Mark C. Liu, Neil Martin, Alberto Papi, Florence Roufosse, Jonathan Stein...> ;Allergy. 2021 Aug 17
• 14 citations
  Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
  Gerald J. Gleich, Florence Roufosse, Geoffrey Chupp, Stanislas Faguer, Bastian Walz, Andreas Reiter, Steven W. Yancey, Jane H Bentley, Jonathan Steinfeld, Gabriel Rica...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2021 Aug 10
• 6 citations
  The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom.
  Gema Requena, John Logie, Daniel C Gibbons, Jonathan Steinfeld, Melissa K. Van Dyke> ;Immunity, Inflammation and Disease. 2021 Jul 22
• 1 citations
  Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
  Isabelle J Pouliquen, Daren Austin, Jonathan Steinfeld, Steven W. Yancey> ;Clinical Therapeutics. 2021 Jun 26
• 11 citations
  Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Datab...
  Mugdha Gokhale, Christopher F. Bell, Scott Doyle, Jolyon Fairburn-Beech, Jonathan Steinfeld, Melissa K. Van Dyke> ;Journal of Clinical Rheumatology. 2021 Apr 1
• 45 citations
  Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
  Atul Gupta, Isabelle Pouliquen, Daren Austin, Robert G. Price, Rodger Kempsford, Jonathan Steinfeld, Eric S. Bradford, Steven W. Yancey> ;Pediatric Pulmonology. 2019 Dec 1
• 54 citations
  Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
  Atul Gupta, Masanori Ikeda, Bob Geng, Jay Azmi, Robert Price, Eric S. Bradford, Steven W. Yancey, Jonathan Steinfeld> ;The Journal of Allergy and Clinical Immunology. 2019 Aug 16
• 74 citations
  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
  Jonathan Steinfeld, Eric S. Bradford, Judith Brown, Stephen Mallett, Steven W. Yancey, Praveen Akuthota, Maria C. Cid, Gerald J. Gleich, David Jayne, Paneez Khoury, Ca...> ;The Journal of Allergy and Clinical Immunology. 2019 Jun 1
• 50 citations
  Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
  Fei Li Kuang, Michael P. Fay, Jean Anne M. Ware, Lauren Wetzler, Nicole Holland-Thomas, Tom Brown, Hector Ortega, Jonathan Steinfeld, Paneez Khoury, Amy D. Klion> ;The Journal of Allergy and Clinical Immunology. in Practice. 2018 Sep 1
• 481 citations
  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
  Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, Maria C. Cid, Raashid...> ;The New England Journal of Medicine. 2017 May 17
• 4 citations
  Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus® in Healthy Adults
  Apinya Bee Vutikullird, Michael Gillespie, Sharon Song, Jonathan Steinfeld> ;Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2016 Apr 8
• 18 citations
  LEAP: A randomized–controlled trial of a lay-educator inpatient asthma education program
  Jessica L. Rice, Kristen M. Matlack, Marsha D. Simmons, Jonathan Steinfeld, Margaret A. Laws, Mark Dovey, Robyn T. Cohen> ;Patient Education and Counseling. 2015 Dec 1
• Join now to see all